Search This Blog

Tuesday, January 7, 2025

Rezolute Breakthrough Designation for Hypoglycemia from Hyperinsulinism

 Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI)

Ersodetug continues to advance in clinical development as a potential treatment for hypoglycemia caused by all forms of hyperinsulinism; topline sunRIZE data expected second half of this year

https://www.globenewswire.com/news-release/2025/01/07/3005336/0/en/Rezolute-Receives-Breakthrough-Therapy-Designation-from-FDA-for-Ersodetug-in-the-Treatment-of-Hypoglycemia-Due-to-Congenital-Hyperinsulinism.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.